Search

Your search keyword '"Correa-Rotter, Ricardo"' showing total 1,026 results
Start Over Author "Correa-Rotter, Ricardo"
1,026 results on '"Correa-Rotter, Ricardo"'

202. Global kidney exchange should expand wisely

Author

Roth, Alvin E., primary, Marino, Ignazio R., additional, Ekwenna, Obi, additional, Dunn, Ty B., additional, Paloyo, Siegfredo R., additional, Tan, Miguel, additional, Correa‐Rotter, Ricardo, additional, Kuhr, Christian S., additional, Marsh, Christopher L., additional, Ortiz, Jorge, additional, Testa, Giuliano, additional, Sindhwani, Puneet, additional, Segev, Dorry L., additional, Rogers, Jeffrey, additional, Punch, Jeffrey D., additional, Forbes, Rachel C., additional, Zimmerman, Michael A., additional, Ellis, Matthew J., additional, Rege, Aparna, additional, Basagoitia, Laura, additional, Krawiec, Kimberly D., additional, and Rees, Michael A., additional

Published
2020
Full Text
View/download PDF

204. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Author

Wheeler, David C, primary, Stefansson, Bergur V, additional, Batiushin, Mikhail, additional, Bilchenko, Oleksandr, additional, Cherney, David Z I, additional, Chertow, Glenn M, additional, Douthat, Walter, additional, Dwyer, Jamie P, additional, Escudero, Elizabeth, additional, Pecoits-Filho, Roberto, additional, Furuland, Hans, additional, Górriz, José Luis, additional, Greene, Tom, additional, Haller, Hermann, additional, Hou, Fan Fan, additional, Kang, Shin-Wook, additional, Isidto, Rey, additional, Khullar, Dinesh, additional, Mark, Patrick B, additional, McMurray, John J V, additional, Kashihara, Naoki, additional, Nowicki, Michal, additional, Persson, Frederik, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Toto, Robert D, additional, Umanath, Kausik, additional, Van Bui, Pham, additional, Wittmann, István, additional, Lindberg, Magnus, additional, Sjöström, C David, additional, Langkilde, Anna Maria, additional, and Heerspink, Hiddo J L, additional

Published
2020
Full Text
View/download PDF

205. P1396EFFECT OF MIXED VERSUS ANIMAL-BASED LOW PHOSPHORUS DIETS IN DIALYSIS PATIENTS ON INTACT FGF23 LEVELS: A RANDOMIZED CLINICAL TRIAL

Author

Ramirez-Sandoval, Juan C, primary, Atilano-Carsi, Ximena, primary, Sánchez-Silva, Jorge, primary, Arce-Santander, Celene, primary, Cruz, Cristino, primary, Basulto-Sosa, Pamela, primary, Tamez-Pedroza, Luis, primary, García de León, Miguel, primary, Espinosa-Cuevas, Ángeles, primary, and Correa-Rotter, Ricardo, primary

Published
2020
Full Text
View/download PDF

207. Prevalence of thyroid dysfunction in healthy adults according to the estimated iodine intake in 24-hour urine samples: The SALMEX cohort

Author

Flores-Rebollar, Armando, primary, Pérez-Díaz, Iván, additional, Vega-Vega, Olynka, additional, Rivera-Moscoso, Raúl, additional, Fagundo-Sierra, Reynerio, additional, Carbajal-Morelos, Sergio L., additional, Osorio-Landa, Hillary K., additional, López-Carrasco, María G., additional, Lira-Reyes, Ana R., additional, and Correa-Rotter, Ricardo, additional

Published
2020
Full Text
View/download PDF

208. The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis

Author

Scholtes, Rosalie A., primary, van Raalte, Daniël H., additional, Correa‐Rotter, Ricardo, additional, Toto, Robert D., additional, Heerspink, Hiddo J. L., additional, Cain, Valerie, additional, Sjöström, C. David, additional, Sartipy, Peter, additional, and Stefánsson, Bergur V., additional

Published
2019
Full Text
View/download PDF

209. Development of an online tool for sodium intake assessment in Mexico

Author

Colín-Ramírez, Eloisa, primary, Cartas-Rosado, Raúl, additional, Miranda Alatriste, Paola Vannesa, additional, Espinosa Cuevas, Ángeles, additional, Arcand, JoAnne, additional, Morales Guerrero, Josefina C, additional, Cassis Nosthas, Lorena, additional, Rivera-Mancía, Susana, additional, Vallejo Allende, Maite, additional, and Correa-Rotter, Ricardo, additional

Published
2019
Full Text
View/download PDF

210. Chronic kidney diseases in agricultural communities: report from a workshop

Author

Mendley, Susan R., primary, Levin, Adeera, additional, Correa-Rotter, Ricardo, additional, Joubert, Bonnie R., additional, Whelan, Elizabeth A., additional, Curwin, Brian, additional, Koritzinsky, Erik H., additional, Gaughan, Denise M., additional, Kimmel, Paul L., additional, Anand, Shuchi, additional, Ordunez, Pedro, additional, Reveiz, Ludovic, additional, Rohlman, Diane S., additional, Scammell, Madeleine K., additional, Wright, Robert O., additional, and Star, Robert A., additional

Published
2019
Full Text
View/download PDF

212. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.

Author

Weir, Matthew R., Gogate, Jagadish, Damaraju, C.V., Correa‐Rotter, Ricardo, and Mahaffey, Kenneth W.

Subjects
MAJOR adverse cardiovascular events, GLOMERULAR filtration rate, PROPORTIONAL hazards models, CANAGLIFLOZIN, TYPE 2 diabetes, CARDIOVASCULAR diseases risk factors
Abstract

Aim: To assess the risk of major adverse cardiovascular events (MACE) of canagliflozin in Hispanic patients with type 2 diabetes (T2D) and high cardiovascular risk or nephropathy with varying levels of kidney function. Materials and Methods: This post hoc analysis included integrated, pooled data from the CANVAS Program and CREDENCE trial. The effects of canagliflozin versus placebo on major adverse cardiovascular events (MACE; i.e. cardiovascular death, non‐fatal myocardial infarction, and non‐fatal stroke) were assessed in subgroups by baseline estimated glomerular filtration rate (eGFR; <45, 45‐60, and >60 mL/min/1.73 m2) overall and in the Hispanic cohort. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models, with subgroup by treatment interaction terms added to test for heterogeneity. Results: A total of 14 543 participants were included; 3029 (20.8%) self‐identified as Hispanic. In the overall population, canagliflozin reduced the risk of MACE compared with placebo (HR, 0.83; 95% CI, 0.75, 0.92), with no heterogeneity observed across eGFR subgroups (interaction P =.22). In the Hispanic cohort, canagliflozin also reduced the risk of MACE (HR, 0.71; 95% CI, 0.55, 0.92), with no heterogeneity by baseline eGFR (interaction P =.25), including among the Hispanic participants at highest risk with a baseline eGFR of less than 45 mL/min/1.73 m2. Conclusion: Canagliflozin reduced the risk of MACE overall, and among Hispanic participants with T2D and high cardiovascular risk or nephropathy in the CANVAS Program and CREDENCE trial, without heterogeneity by baseline eGFR. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

214. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

Author

Smeijer, J. David, Koomen, Jeroen, Kohan, Donald E., McMurray, John J.V., Bakris, George L., Correa-Rotter, Ricardo, Hou, Fan-Fan, Januzzi, James L., Kitzman, Dalane W., Kolansky, Daniel M., Makino, Hirofumi, Perkovic, Vlado, Tobe, Sheldon, Parving, Hans-Henrik, de Zeeuw, Dick, and Heerspink, Hiddo J.L.

Abstract

The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with a numerically higher incidence of heart failure (HF) hospitalization.

Published
2022
Full Text
View/download PDF

215. Chronic Kidney Diseases in Agricultural Communities Report from a Workshop

Author

Mendley, Susan R., Levin, Adeera, Correa-Rotter, Ricardo, Joubert, Bonnie, Whelan, Elizabeth, Curwin, Brian, Koritzinsky, Erik, Gaughan, Denise, Kimmel, Paul L., Anand, Shuchi, Ordunez, Pedro, Reveiz, Ludovic, Rohlman, Diane S., Saenz, Carla, Scammell, Madeleine K., Wright, Robert O., and Star, Robert A.

Subjects
0301 basic medicine, business.industry, 030232 urology & nephrology, Psychological intervention, Capacity building, Disease, Environmental exposure, Article, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Nephrology, Agriculture, Low and middle income countries, Research strategies, Chronic Kidney Diseases, Political science, Engineering ethics, business
Abstract

In June 2018, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Environmental Health Sciences sponsored a workshop to identify research gaps in an increasingly common form of chronic kidney disease in agricultural communities, often termed "CKDu." The organizers invited a broad range of experts who provided diverse expertise and perspectives, many of whom had never addressed this particular epidemic. Discussion was focused around selected topics, including identifying and mitigating barriers to research in CKDu, creating a case definition, and defining common data elements. All hypotheses regarding etiology were entertained, and meeting participants discussed potential research strategies, choices in study design, and novel tools that may prove useful in this disease. Achievements of the workshop included robust cross-disciplinary discussion and preliminary planning of research goals and design. Specific challenges in implementing basic and clinical research and interventions in low- and middle-income countries were recognized. A balanced approach to leveraging local resources and capacity building without overreaching was emphasized.

Published
2019

218. In Memoriam

Author

CORREA-ROTTER, RICARDO

Published
2005

220. Prevention of chronic kidney and vascular disease: Toward global health equity—The Bellagio 2004 Declaration

Author

DIRKS, JOHN H., DE ZEEUW, DICK, AGARWAL, SANJAY K., ATKINS, ROBERT C., CORREA-ROTTER, RICARDO, DʼAMICO, GIUSEPPE, BENNETT, PETER H., EL NAHAS, MEGUID, VALDES, RAUL HERRERA, KASEJE, DAN, KATZ, IVOR J., NAICKER, SARALA, RODRIGUEZ-ITURBE, BERNARDO, SCHIEPPATI, ARRIGO, SHAHEEN, FAISSAL, SITTHI-AMORN, CHITR, SOLEZ, KIM, VIBERTI, GIANCARLO, REMUZZI, GIUSEPPE, and WEENING, JAN J.

Published
2005

221. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Author

UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Heerspink, Hiddo J L, Parving, Hans-Henrik, Andress, Dennis L, Bakris, George, Correa-Rotter, Ricardo, Hou, Fan-Fan, Kitzman, Dalane W, Kohan, Donald, Makino, Hirofumi, McMurray, John J V, Melnick, Joel Z, Miller, Michael G, Pergola, Pablo E, Perkovic, Vlado, Tobe, Sheldon, Yi, Tingting, Wigderson, Melissa, de Zeeuw, Dick, SONAR Committees and Investigators, Jadoul, Michel, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Heerspink, Hiddo J L, Parving, Hans-Henrik, Andress, Dennis L, Bakris, George, Correa-Rotter, Ricardo, Hou, Fan-Fan, Kitzman, Dalane W, Kohan, Donald, Makino, Hirofumi, McMurray, John J V, Melnick, Joel Z, Miller, Michael G, Pergola, Pablo E, Perkovic, Vlado, Tobe, Sheldon, Yi, Tingting, Wigderson, Melissa, de Zeeuw, Dick, SONAR Committees and Investigators, and Jadoul, Michel

Abstract

BACKGROUND: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. METHODS: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18-85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25-75 mL/min per 1·73 m2 of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g who had received maximum labelled or tolerated renin-angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders) were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days) or end-stage kidney disease (eGFR <15 mL/min per 1·73 m2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure) in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. FINDINGS: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325) or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4-2·9). 79 (6·0%) of

Published
2019

222. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR):a double-blind, randomised, placebo-controlled trial

Author

Heerspink, Hiddo J.L., Parving, Hans Henrik, Andress, Dennis L., Bakris, George, Correa-Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John J.V., Melnick, Joel Z., Miller, Michael G., Pergola, Pablo E., Perkovic, Vlado, Tobe, Sheldon, Yi, Tingting, Wigderson, Melissa, de Zeeuw, Dick, Elbert, Alicia, Vallejos, Augusto, Alvarisqueta, Andres, Maffei, Laura, Juncos, Luis, de Arteaga, Javier, Greloni, Gustavo, Farias, Eduardo, Zucchini, Alfredo, Vogel, Daniel, Cusumano, Ana, Santos, Juan, Fraenkel, Margaret, Gallagher, Martin, Davis, Tim, Acharya, Shamasunder, Cooke, Duncan, Suranyi, Michael, Roger, Simon, Toussaint, Nigel, Pollock, Carol, Chan, Doris, Stranks, Stephen, MacIsaac, Richard, Endre, Zoltan, Schmidt, Alice, Prager, Rudolf, Mayer, Gert, Warling, Xavier, Jadoul, Michel, Egstrup, Kenneth, Oczachowska-Kulik, Anna Ewa, Rossing, Peter, Ono, Yasuhirov, Yalcin, Murat, Karim, Shahana, Heerspink, Hiddo J.L., Parving, Hans Henrik, Andress, Dennis L., Bakris, George, Correa-Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John J.V., Melnick, Joel Z., Miller, Michael G., Pergola, Pablo E., Perkovic, Vlado, Tobe, Sheldon, Yi, Tingting, Wigderson, Melissa, de Zeeuw, Dick, Elbert, Alicia, Vallejos, Augusto, Alvarisqueta, Andres, Maffei, Laura, Juncos, Luis, de Arteaga, Javier, Greloni, Gustavo, Farias, Eduardo, Zucchini, Alfredo, Vogel, Daniel, Cusumano, Ana, Santos, Juan, Fraenkel, Margaret, Gallagher, Martin, Davis, Tim, Acharya, Shamasunder, Cooke, Duncan, Suranyi, Michael, Roger, Simon, Toussaint, Nigel, Pollock, Carol, Chan, Doris, Stranks, Stephen, MacIsaac, Richard, Endre, Zoltan, Schmidt, Alice, Prager, Rudolf, Mayer, Gert, Warling, Xavier, Jadoul, Michel, Egstrup, Kenneth, Oczachowska-Kulik, Anna Ewa, Rossing, Peter, Ono, Yasuhirov, Yalcin, Murat, and Karim, Shahana

Abstract

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR

Published
2019

230. Two-Year Effects of Alendronate on Bone Mineral Density and Vertebral Fracture in Patients Receiving Glucocorticoids: A Randomized, Double-Blind, Placebo-Controlled Extension Trial

Author

Adachi, Jonathan D., Saag, Kenneth G., Delmas, Pierre D., Liberman, Uri A., Emkey, Ronald D., Seeman, Ego, Lane, Nancy E., Kaufman, Jean-Marc, Poubelle, Patrice E. E., Hawkins, Federico, Correa-Rotter, Ricardo, Menkes, Charles-Joel, Rodriguez-Portales, Jose A., Schnitzer, Thomas J., Block, Joel A., Wing, Jeffrey, McIlwain, Harris H., Westhovens, Rene, Brown, Jacques, Melo-Gomes, Jose A., Gruber, Barry L., Yanover, Melissa J., Leite, Maria Odette R., Siminoski, Kerry G., Nevitt, Michael C., Sharp, John T., Malice, Marie-Pierre, Dumortier, Thomas, Czachur, Michelle, Carofano, Wendy, and Daifotis, Anastasia

Published
2001

232. Prolonged Intermittent Renal Replacement Therapy for Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome.

Author

Ramirez-Sandoval, Juan C., Gaytan-Arocha, Jorge E., Xolalpa-Chávez, Pedro, Mejia-Vilet, Juan M., Arvizu-Hernandez, Mauricio, Rivero-Sigarroa, Eduardo, Torruco-Sotelo, Carlos, Correa-Rotter, Ricardo, and Vega-Vega, Olynka

Subjects
COVID-19, ADULT respiratory distress syndrome, ACUTE kidney failure, RENAL replacement therapy, ARTIFICIAL respiration, COVID-19 pandemic, KIDNEY transplantation, HYPERLACTATEMIA
Abstract

Introduction: Patients with acute respiratory distress syndrome (ARDS) secondary to COVID-19 frequently develop severe acute kidney injury (AKI). Although continuous renal replacement therapy is the standard of care for critically ill patients, prolonged intermittent renal replacement therapy (PIRRT) may be a feasible option. We aimed to describe the tolerability and security of PIRRT treatments in COVID-19 patients with ARDS who required mechanical ventilation and developed severe AKI. Methods: We prospectively analyzed patients who underwent PIRRT treatments at a COVID-19 reference hospital in Mexico City. Intradialytic hypotension was defined as a systolic blood pressure decrease of ≥20 mm Hg or an increase of 100% in vasopressor dose. Results: We identified 136 AKI cases (60.7%) in 224 patients admitted to the intensive care unit. Among them, 21 (15%) underwent PIRRT (130 sessions) due to stage 3 AKI. The median age of the cohort was 49 (range 36–73) years, 17 (81%) were male, 7 (33%) had diabetes, and the median time between symptoms onset and PIRRT initiation was 12 (interquartile range [IQR] 7–14) days. The median of PIRRT procedures for each patient was 5 (IQR 4–9) sessions. In 108 (83%) PIRRT sessions, the total ultrafiltration goal was achieved. In 84 (65%) PIRRT procedures, there was a median increase in norepinephrine dose of +0.031 mcg/kg/min during PIRRT (IQR 0.00 to +0.07). Intradialytic hypotensive events occurred in 56 (43%) procedures. Fifteen (12%) PIRRT treatments were discontinued due to severe hypotension. Vasopressor treatment at PIRRT session onset (OR 6.2, 95% CI 1.4–28.0, p: 0.02) and a pre-PIRRT lactate ≥3.0 mmol/L (OR 4.63, 95% CI 1.3–12.8, p: 0.003) were independently and significantly associated with the risk of hypotension during PIRRT. During follow-up, 11 patients (52%) recovered from AKI and respiratory failure and 9 (43%) died. Several adaptations to our PIRRT protocol during the COVID-19 outbreak are presented. Conclusions: PIRRT was feasible in the majority of COVID-19 patients with ARDS and severe AKI, despite frequent transitory intradialytic hypotensive episodes. PIRRT may represent an acceptable alternative of renal replacement therapy during the COVID-19 outbreak. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

233. The authors reply

Author

Pecoits-Filho, Roberto, primary, Sola, Laura, additional, Correa-Rotter, Ricardo, additional, Claure-Del Granado, Rolando, additional, Douthat, Walter G., additional, and Bellorin-Font, Ezequiel, additional

Published
2019
Full Text
View/download PDF

234. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE)

Author

Gonzalez-Quiroz, Marvin, primary, Nitsch, Dorothea, additional, Hamilton, Sophie, additional, O'Callaghan Gordo, Cristina, additional, Saran, Rajiv, additional, Glaser, Jason, additional, Correa-Rotter, Ricardo, additional, Jakobsson, Kristina, additional, Singh, Ajay, additional, Gunawardena, Nalika, additional, Levin, Adeera, additional, Remuzzi, Giuseppe, additional, Caplin, Ben, additional, and Pearce, Neil, additional

Published
2019
Full Text
View/download PDF

237. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Author

Heerspink, Hiddo J L, primary, Parving, Hans-Henrik, additional, Andress, Dennis L, additional, Bakris, George, additional, Correa-Rotter, Ricardo, additional, Hou, Fan-Fan, additional, Kitzman, Dalane W, additional, Kohan, Donald, additional, Makino, Hirofumi, additional, McMurray, John J V, additional, Melnick, Joel Z, additional, Miller, Michael G, additional, Pergola, Pablo E, additional, Perkovic, Vlado, additional, Tobe, Sheldon, additional, Yi, Tingting, additional, Wigderson, Melissa, additional, de Zeeuw, Dick, additional, Elbert, Alicia, additional, Vallejos, Augusto, additional, Alvarisqueta, Andres, additional, Maffei, Laura, additional, Juncos, Luis, additional, de Arteaga, Javier, additional, Greloni, Gustavo, additional, Farias, Eduardo, additional, Zucchini, Alfredo, additional, Vogel, Daniel, additional, Cusumano, Ana, additional, Santos, Juan, additional, Fraenkel, Margaret, additional, Gallagher, Martin, additional, Davis, Tim, additional, Acharya, Shamasunder, additional, Cooke, Duncan, additional, Suranyi, Michael, additional, Roger, Simon, additional, Toussaint, Nigel, additional, Pollock, Carol, additional, Chan, Doris, additional, Stranks, Stephen, additional, MacIsaac, Richard, additional, Endre, Zoltan, additional, Schmidt, Alice, additional, Prager, Rudolf, additional, Mayer, Gert, additional, Warling, Xavier, additional, Jadoul, Michel, additional, Hougardy, Jean, additional, Vercammen, Chris, additional, Van Vlem, Bruno, additional, Gillard, Pieter, additional, Costa e Forti, Adriana, additional, Borges, Joao Lindolfo, additional, Santos Canani, Luis, additional, Eliaschewitz, Freddy, additional, Leite, Silmara, additional, Fraige Filho, Fadlo, additional, Paschoalin, Raphael, additional, Moura Neto, Jose Andrade, additional, Deboni, Luciane, additional, de Lourdes Noronha, Irene, additional, Cercato, Cintia, additional, Prompt, Carlos Alberto, additional, Zanella, Maria, additional, Rassi, Nelson, additional, D'Avila, Domingos, additional, Milagres, Rosangela, additional, Felicio, Joao, additional, Pecoits Filho, Roberto, additional, Riella, Miguel Carlos, additional, Salles, Joao, additional, Keitel, Elizete, additional, Draibe, Sergio, additional, Amodeo, Celso, additional, Youmbissi, Joseph, additional, Roy, Louise, additional, Cournoyer, Serge, additional, Jolly, Shivinder, additional, Pichette, Vincent, additional, Nesrallah, Gihad, additional, Bajaj, Harpreet Singh, additional, Khandwala, Hasnain, additional, Aronson, Ronnie, additional, Goluch, Richard, additional, Tam, Paul, additional, Rabbat, Christian, additional, Bailey, Gordon, additional, Chow, Stephen, additional, Castillo, Alvaro, additional, Danin Vargas, Alfredo, additional, Gonzalez, Fernando, additional, Munoz, Rodrigo, additional, Gutierrez, Vicente, additional, Godoy, Gonzalo, additional, Zhao, Hongwen, additional, Liu, Zhangsuo, additional, Zhao, Minghui, additional, Guo, Xiaohui, additional, Su, Benli, additional, Fu, Shuxia, additional, Xu, Yan, additional, Yang, Jinkui, additional, Shi, Bingyin, additional, Xiao, Guanqing, additional, Shi, Wei, additional, Hao, Chuanming, additional, Xing, Changying, additional, Hou, Fanfan, additional, Luo, Qun, additional, Li, Yuxiu, additional, Ji, Linong, additional, Zuo, Li, additional, Wang, Song, additional, Ni, Zhaohui, additional, Ding, Guohua, additional, Chen, Nan, additional, Zhao, Jiajun, additional, Jia, Weiping, additional, Yu, Shengqiang, additional, Weng, Jian, additional, Xu, Gang, additional, Fu, Ping, additional, Sun, Shiren, additional, Liu, Bicheng, additional, Ding, Xiaoqiang, additional, Rychlik, Ivan, additional, Oplustilova, Alexandra, additional, Bartaskova, Dagmar, additional, Honova, Vaclava, additional, Chmelickova, Hana, additional, Petr, Martin, additional, Bucek, Petr, additional, Tesar, Vladimir, additional, Zahumensky, Emil, additional, Povlsen, Johan, additional, Egstrup, Kenneth, additional, Oczachowska-Kulik, Anna, additional, Rossing, Peter, additional, Lahtela, Jorma, additional, Strand, Jorma, additional, Kantola, Ilkka, additional, Petit, Catherine, additional, Combe, Christian, additional, Zaoui, Philippe, additional, Esnault, Vincent, additional, Urena Torres, Pablo, additional, Halimi, Jean-Michel, additional, Dussol, Bertrand, additional, Bieler, Tasso, additional, Budde, Klemens, additional, Dellanna, Frank, additional, Segiet, Thomas, additional, Kosch, Christine, additional, Schmidt-Guertler, Hans, additional, Schenkenberger, Isabelle, additional, Vielhauer, Volker, additional, Pistrosch, Frank, additional, Alscher, Mark, additional, Hasslacher, Christoph, additional, Hugo, Christian, additional, Muehlfeld, Anja, additional, Wanner, Christoph, additional, Passadakis, Ploumis, additional, Apostolou, Theofanis, additional, Tentolouris, Nikolaos, additional, Stefanidis, Ioannis, additional, Mavromatidis, Konstantinos, additional, Liakopoulos, Vasilios, additional, Goumenos, Dimitrios, additional, Siamopoulos, Konstantinos, additional, Yeung, Vincent, additional, Ozaki, Risa, additional, Fung, Samuel, additional, Tan, Kathryn, additional, Tang, Sydney, additional, Lui, Sing Leung, additional, Cheung, Siu Fai, additional, Sreenan, Seamus, additional, Eustace, Joseph, additional, O'Shea, Donal, additional, Lavin, Peter, additional, Stack, Austin, additional, Yagil, Yoram, additional, Wainstein, Julio, additional, Knobler, Hilla, additional, Cohen, Josef, additional, Kenis, Irina, additional, Daoud, Deeb, additional, Bar-Dayan, Yosefa, additional, Frajewicki, Victor, additional, Adawi, Faiad, additional, Gesualdo, Loreto, additional, Santoro, Domenico, additional, Marino, Francesco, additional, Galfre, Andrea, additional, Brunati, Chiara, additional, Ruggenenti, Piero, additional, Rombola, Giuseppe, additional, Pugliese, Giuseppe, additional, Ravera, Maura, additional, Malberti, Fabio, additional, Pontoriero, Giuseppe, additional, Rampino, Teresa, additional, De Cosmo, Salvatore, additional, Esposito, Ciro, additional, Nappi, Felice, additional, Abaterusso, Cataldo, additional, Conte, Giuseppe, additional, Panichi, Vincenzo, additional, Lauro, Davide, additional, Capasso, Giovambattista, additional, Russo, Domenico, additional, Anzai, Jiichi, additional, Naka, Motoji, additional, Ato, Keita, additional, Tsujimoto, Tetsuro, additional, Nimura, Toshinori, additional, Nakashima, Eitaro, additional, Takeda, Tetsuro, additional, Fujii, Shinya, additional, Kobayashi, Kunihisa, additional, Iwaoka, Hideaki, additional, Nagayama, Koji, additional, Harada, Hiroyuki, additional, Maeda, Hajime, additional, Kishimoto, Rui, additional, Iitsuka, Tadashi, additional, Itabashi, Naoki, additional, Furuya, Ryuichi, additional, Maeda, Yoshitaka, additional, Yamada, Daishiro, additional, Sasaki, Nobuhiro, additional, Sasaki, Hiromitsu, additional, Ueda, Shinichiro, additional, Kashihara, Naoki, additional, Watanabe, Shuichi, additional, Nakamura, Takehiro, additional, Kanai, Hidetoshi, additional, Makita, Yuichiro, additional, Ono, Keiko, additional, Iehara, Noriyuki, additional, Goto, Daisuke, additional, Kosuge, Keiichiro, additional, Tsuchida, Kenichi, additional, Sato, Toshiaki, additional, Sekikawa, Takashi, additional, Okamoto, Hideki, additional, Tanaka, Tsuyoshi, additional, Ikeda, Naoko, additional, Tadika, Takenobu, additional, Mukasa, Koji, additional, Osonoi, Takeshi, additional, Hirano, Fuminori, additional, Nishimura, Motonobu, additional, Yambe, Yuko, additional, Tanaka, Yukio, additional, Ujihara, Makoto, additional, Sakai, Takashi, additional, Imura, Mitsuo, additional, Umayahara, Yutaka, additional, Makino, Shinya, additional, Nakazawa, Jun, additional, Yamaguchi, Yukinari, additional, Kashine, Susumu, additional, Miyaoka, Hiroaki, additional, Suzuki, Katsunori, additional, Inoue, Toshihiko, additional, Nagai, Sou, additional, Sato, Nobuyuki, additional, Yamamoto, Masahiro, additional, Taya, Noriyasu, additional, Fujita, Akira, additional, Matsutani, Akira, additional, Shibagaki, Yugo, additional, Sato, Yuichi, additional, Yamauchi, Akira, additional, Tsutsui, Masahiro, additional, Ishiko, Tamayo, additional, Kaneko, Shizuka, additional, Azuma, Nobuyuki, additional, Matsuda, Hirofumi, additional, Hashiguchi, Yasuhiro, additional, Onishi, Yukiko, additional, Tokui, Mikiya, additional, Matsuhisa, Munehide, additional, Kiyosue, Arihiro, additional, Shinoda, Junji, additional, Ishikawa, Kazuo, additional, Ahmad, Ghazali, additional, Vijayasingham, Shalini, additional, Aziz, Nor Azizah, additional, Hussein, Zanariah, additional, Fung, Yin Khet, additional, Hassan, Wan Hasnul Halimi Wan, additional, Wong, Hin Seng, additional, Goh, Bak Leong, additional, Ali, Norhaliza Mohd, additional, Merican, Nor Shaffinaz Yusuf Azmi, additional, Vaithilingam, Indralingam, additional, Nik Ahmad, Nik Nur Fatnoon, additional, Adam, Noor, additional, Sukor, Norlela, additional, Vengadasalam, V Paranthaman P, additional, Abdul Kadir, Khalid, additional, Mohamed, Mafauzy, additional, Renoirte Lopez, Karina, additional, Leguizamo-Dimas, Aniceto, additional, Chew Wong, Alfredo, additional, Chevaile-Ramos, Jose, additional, Gonzalez Gonzalez, Jose, additional, Rico Hernandez, Raul, additional, Nino-Cruz, Jose, additional, Sauque Reyna, Leobardo, additional, Gonzalez-Galvez, Guillermo, additional, Madero Rovalo, Magdalena, additional, Bochicchio-Ricardelli, Tomasso, additional, Aldrete, Jorge, additional, Carranza-Madrigal, Jaime, additional, Vogt, Liffert, additional, Smak Gregoor, Peter, additional, Barendregt, JNM, additional, Luik, Peter, additional, Gansevoort, Ronald, additional, Laverman, Gozewijn, additional, Pilmore, Helen, additional, Lunt, Helen, additional, Baker, John, additional, Miller, Steven, additional, Rabindranath, Kannaiyan, additional, Zapata-Rincon, Luis, additional, Vargas-Gonzales, Rolando, additional, Calderon Ticona, Jorge, additional, Dextre Espinoza, Augusto, additional, Burga Nunez, Jose, additional, Zea-Nunez, Carlos Antonio, additional, Herrada Orue, Benjamin, additional, Medina-Santander, Boris, additional, Delgado-Butron, Cesar, additional, Farfan-Aspilcueta, Julio, additional, Mazur, Stanislaw, additional, Necki, Miroslaw, additional, Wruk, Michal, additional, Klodawska, Katarzyna, additional, Popenda, Grazyna, additional, Skokowska, Ewa, additional, Arciszewska, Malgorzata, additional, Wiecek, Andrzej, additional, Ciechanowski, Kazimierz, additional, Nowicki, Michal, additional, Birne, Rita, additional, Cabrita, Antonio, additional, Ramos, Aura, additional, Antunes Ferreira, Manuel Anibal, additional, Matta Fontanet, Evelyn, additional, Alcantara-Gonzalez, Altagracia Aurora, additional, Comulada-Rivera, Angel, additional, Galindo Ramos, Eugenia, additional, Cangiano, Jose, additional, Quesada-Suarez, Luis, additional, Calderon Ortiz, Ricardo, additional, Vazquez-Tanus, Jose, additional, Burgos-Calderon, Rafael, additional, Rosado, Carlos, additional, Hancu, Nicolae, additional, Pintilei, Ella, additional, Mistodie, Cristina, additional, Bako, Gabriel, additional, Ionutiu, Lavinia, additional, Petrica, Ligia, additional, Timar, Romulus, additional, Tuta, Liliana, additional, Duma, Livia, additional, Tutescu, Adriana, additional, Ivanova, Svetlana, additional, Essaian, Ashot, additional, Zrazhevskiy, Konstantin, additional, Tomilina, Natalia, additional, Smolyarchuk, Elena, additional, Kuzin, Anatoly, additional, Lantseva, Olga, additional, Karpova, Irina, additional, Shamkhalova, Minara, additional, Liberanskaya, Natalia, additional, Yavdosyuk, Andrey, additional, Shvarts, Yuri, additional, Bardymova, Tatiana, additional, Blagoveshchenskaya, Olga, additional, Solovev, Oleg, additional, Rechkova, Elena, additional, Pikalova, Natalia, additional, Pavlova, Maria, additional, Kolmakova, Elena, additional, Sayfutdinov, Rustam, additional, Villevalde, Svetlana, additional, Koziolova, Natalya, additional, Martynenko, Vladimir, additional, Marasaev, Vyacheslav, additional, Maksudova, Adelya, additional, Sigitova, Olga, additional, Mordovin, Viktor, additional, Klimontov, Vadim, additional, Samoylova, Yulia, additional, Karonova, Tatiana, additional, Yeoh, Lee Ying, additional, Teo, Boon Wee, additional, Foo, Marjorie Wai Yin, additional, Liew, Adrian, additional, Tkac, Ivan, additional, Oroszova, Aniko, additional, Fekete, Jozef, additional, Rosenberger, Jaroslav, additional, Obetkova, Ida, additional, Fulopova, Alla, additional, Kolesarova, Eva, additional, Raslova, Katarina, additional, Smolko, Peter, additional, Oksa, Adrian, additional, Distiller, Larry, additional, Trokis, Julien, additional, Adams, Luthando, additional, Makan, Hemant, additional, Ramlachan, Padaruth, additional, Mitha, Essack, additional, Coetzee, Kathleen, additional, Punt, Zelda, additional, Bhorat, Qasim, additional, Naiker, Puvenesvari, additional, Ellis, Graham, additional, Van Zyl, Louis, additional, Lee, Kwan Woo, additional, Kim, Min Seon, additional, Yoo, Soon-Jib, additional, Yoon, Kun Ho, additional, Cho, Yong-Wook, additional, Park, Tae-Sun, additional, Kim, Sang Yong, additional, Choi, Moon-Gi, additional, Oh, Tae Keun, additional, Lee, Kang-Wook, additional, Shon, Ho Sang, additional, Suh, Sung Hwan, additional, Kim, Byung-Joon, additional, Doo-Man, Kim, additional, Yi, Joo Hark, additional, Lee, Sang Ah, additional, Cho, Ho Chan, additional, Kim, Sin-Gon, additional, Cha, Dae-Ryong, additional, Seo, Ji A, additional, Choi, Kyung Mook, additional, Woo, Jeong-Taek, additional, Ahn, Kyu Jeung, additional, Lee, Jae Hyuk, additional, Kim, In-Joo, additional, Lee, Moon-Kyu, additional, Jang, Hak Chul, additional, Park, Kyong-Soo, additional, Kim, Beom Seok, additional, Mok, Ji Oh, additional, Shin, Mijung, additional, Yoon, Sun Ae, additional, Nam-Goong, Il-Seong, additional, Chung, Choon Hee, additional, Yu, Tae Yang, additional, Lee, Hyoung Woo, additional, Soto Gonzalez, Alfonso, additional, Almirall, Jaume, additional, Egido, Jesus, additional, Calero Gonzalez, Francesca, additional, Fernandez Fresnedo, Gema, additional, Valera Cortes, Ildefonso, additional, Praga Terente, Manuel, additional, Garcia Mendez, Isabel, additional, Navarro Gonzalez, Juan, additional, Herrero Calvo, Jose, additional, Cigarran Guldris, Secundino, additional, Prieto Velasco, Mario, additional, Minguela Pesquera, Jose Ignacio, additional, Galan, Antonio, additional, Pascual, Julio, additional, Marques Vidas, Maria, additional, Martins Munoz, Judith, additional, Rodriguez-Perez, Jose, additional, Castro-Alonso, Cristina, additional, Bonet Sol, Josep, additional, Seron, Daniel, additional, Fernandez Giraldez, Elvira, additional, Arrieta Lezama, Javier, additional, Montero, Nuria, additional, Hernandez-Jaras, Julio, additional, Santamaria Olmo, Rafael, additional, Molas Coten, Jose Ramon, additional, Hellberg, Olof, additional, Fellstrom, Bengt, additional, Bock, Andreas, additional, Pei, Dee, additional, Lin, Ching-Ling, additional, Tien, Kai-Jen, additional, Chen, Ching-Chu, additional, Huang, Chien-Ning, additional, Jiang, Ju-Ying, additional, Wu, Du-An, additional, Chu, Chih-Hsun, additional, Tseng, Shih-Ting, additional, Chen, Jung-Fu, additional, Bau, Cho-Tsan, additional, Sheu, Wayne, additional, Wu, Mai-Szu, additional, Sari, Ramazan, additional, Sezer, Siren, additional, Yildiz, Alaattin, additional, Satman, Ilhan, additional, Kalender, Betul, additional, Mankovskyy, Borys, additional, Fushtey, Ivan, additional, Stanislavchuk, Mykola, additional, Kolenyk, Mykola, additional, Dudar, Iryna, additional, Zolotaikina, Viktoriia, additional, Abrahamovych, Orest, additional, Kostynenko, Tetyana, additional, Petrosyan, Olena, additional, Kuskalo, Petro, additional, Galushchak, Olga, additional, Legun, Oleg, additional, Topchii, Ivan, additional, Martynyuk, Liliya, additional, Stryzhak, Vasyl, additional, Panina, Svitlana, additional, Tkach, Sergii, additional, Korpachev, Vadym, additional, Maxwell, Peter, additional, Gnudi, Luigi, additional, Kon, Sui Phin, additional, Tindall, Hilary, additional, Kalra, Phillip, additional, Mark, Patrick, additional, Patel, Dipesh, additional, El-Shahawy, Mohamed, additional, Bai, Liqun, additional, Nica, Romanita, additional, Lien, Yeong-Hau, additional, Menefee, Judson, additional, Busch, Robert, additional, Miller, Alan, additional, Ahmed, Azazuddin, additional, Arif, Ahmed, additional, Lee, Joseph, additional, Desai, Sachin, additional, Bansal, Shweta, additional, Bentsianov, Marie, additional, Belledonne, Mario, additional, Jere, Charles, additional, Gaona, Raul, additional, Greenwood, Gregory, additional, Brusco, Osvaldo, additional, Boiskin, Mark, additional, Belo, Diogo, additional, Minasian, Raffi, additional, Atray, Naveen, additional, Lawrence, Mary, additional, Taliercio, John, additional, Pergola, Pablo, additional, Scott, David, additional, Alvarez, German, additional, Marder, Bradley, additional, Powell, Thomas, additional, Bakdash, Wa'el, additional, Stoica, George, additional, McFadden, Christopher, additional, Rendell, Marc, additional, Wise, Jonathan, additional, Jones, Audrey, additional, Jardula, Michael, additional, Madu, Ivy-Joan, additional, Varghese, Freemu, additional, Tulloch, Brian, additional, Ahmed, Ziauddin, additional, Hames, Melanie, additional, Nazeer, Imran, additional, Shahid, Newman, additional, John, Rekha, additional, Montero, Manuel, additional, Fitz-Patrick, David, additional, Phillips, Lawrence, additional, Guasch, Antonio, additional, Christofides, Elena, additional, Gundroo, Aijaz, additional, Amin, Mohammad, additional, Bowman-Stroud, Cynthia, additional, Link, Michael, additional, Mulloy, Laura, additional, Nammour, Michael, additional, Lalwani, Tarik, additional, Hanson, Lenita, additional, Whaley-Connell, Adam, additional, Herman, Lee, additional, Chatha, Rupi, additional, Osama, Sayed, additional, Liss, Kenneth, additional, Kayali, Zeid, additional, Bhargava, Anuj, additional, Israel, Ezra, additional, Peguero-Rivera, Alfredo, additional, Fang, Michael, additional, Slover, Judith, additional, Barengolts, Elena, additional, Flores, Jose, additional, Muoneke, Rosemary, additional, Savin, Virginia, additional, Awua-Larbi, Stella, additional, Levine, Andrew, additional, Newman, George, additional, Golestaneh, Laden, additional, Bohm, Guillermo, additional, Reisin, Efrain, additional, Cruz, Lucita, additional, Weiss, Robert, additional, Zieve, Franklin, additional, Horwitz, Edward, additional, Chuang, Peale, additional, Mersey, James, additional, Manley, John, additional, Graf, Ronald, additional, Bedros, Fadi, additional, Joshi, Sudhir, additional, Frias, Juan, additional, Assefi, Ali, additional, O'Shaughnessy, Andrew, additional, Brantley, Roman, additional, Minga, Todd, additional, Tietjen, David, additional, Kantor, Samuel, additional, Jamal, Aamir, additional, Guadiz, Ramon, additional, Hershon, Kenneth, additional, Bressler, Peter, additional, Kopyt, Nelson, additional, Cathcart, Harold, additional, Bloom, Scott, additional, Reichel, Ronald, additional, Nakhle, Samer, additional, Dulude, Emily, additional, Tarkan, Joshua, additional, Baker, Penelope, additional, Zeig, Steven, additional, Moya Hechevarria, Jaynier, additional, Ropero-Cartier, Armando, additional, De la Calle, Gilda, additional, Doshi, Ankur, additional, Saba, Fadi, additional, Sligh, Teresa, additional, Shaw, Sylvia, additional, Kumar, Jayant, additional, Szerlip, Harold, additional, Bayliss, George, additional, Perlman, Alan, additional, Sakhrani, Lakhi, additional, Gouge, Steven, additional, Argoud, Georges, additional, Acosta, Idalia, additional, Elder, John, additional, Joshi, Sucharit, additional, Sensenbrenner, John, additional, Vicks, Steven, additional, Mangoo-Karim, Roberto, additional, Galphin, Claude, additional, Leon-Forero, Carlos, additional, Gilbert, John, additional, Brown, Eric, additional, Ijaz, Adeel, additional, Butt, Salman, additional, Markell, Mariana, additional, Arauz-Pacheco, Carlos, additional, Sloan, Lance, additional, Alvarado, Odilon, additional, Jabbour, Serge, additional, Simon, Eric, additional, Rastogi, Anjay, additional, James, Sam, additional, Hall, Karen, additional, Melish, John, additional, Dixon, Brad, additional, Adolphe, Allen, additional, Kovesdy, Csaba, additional, Beddhu, Srinivasan, additional, Solomon, Richard, additional, Fernando, Ronald, additional, Levin, Ellis, additional, Thakar, Charuhas, additional, Robey, Brooks, additional, Goldfarb, David, additional, Fried, Linda, additional, Maddukuri, Geetha, additional, Thomson, Stephen, additional, Annand, Andrew, additional, Kronfli, Saeed, additional, Kalirao, Paramjit, additional, Schmidt, Rebecca, additional, Dahl, Neera, additional, Blumenthal, Samuel, additional, Weinstein, Debra, additional, Ostergaard, Ove, additional, Weinstein, Talia, additional, Ono, Yasuhiro, additional, Yalcin, Murat, additional, and Karim, Shahana, additional

Published
2019
Full Text
View/download PDF

243. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Author

Rossing, Peter, Inzucchi, Silvio E, Vart, Priya, Jongs, Niels, Docherty, Kieran F, Jhund, Pardeep S, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Lindberg, Magnus, Langkilde, Anna Maria, Sjöstrand, Mikaela, Stefansson, Bergur V, Karlsson, Cecilia, Chertow, Glenn M, Hou, Fan Fan, Correa-Rotter, Ricardo, Toto, Robert D, Wheeler, David C, McMurray, John J V, and Heerspink, Hiddo J L

Abstract

Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the DAPA-CKD and DAPA-HF trials.

Published
2022
Full Text
View/download PDF

246. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

Author

McMurray, John J.V., Wheeler, David C., Stefánsson, Bergur V., Jongs, Niels, Postmus, Douwe, Correa-Rotter, Ricardo, Chertow, Glenn M., Hou, Fan Fan, Rossing, Peter, Sjöström, C. David, Solomon, Scott D., Toto, Robert D., Langkilde, Anna Maria, and Heerspink, Hiddo J.L.

Abstract

The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF).

Published
2021
Full Text
View/download PDF

247. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Author

Jongs, Niels, Greene, Tom, Chertow, Glenn M, McMurray, John J V, Langkilde, Anna Maria, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C David, Stefansson, Bergur V, Toto, Robert D, Wheeler, David C, and Heerspink, Hiddo J L

Abstract

Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chronic kidney disease with and without type 2 diabetes in the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.

Published
2021
Full Text
View/download PDF

248. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Author

Heerspink, Hiddo J L, Jongs, Niels, Chertow, Glenn M, Langkilde, Anna Maria, McMurray, John J V, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C David, Stefansson, Bergur V, Toto, Robert D, Wheeler, David C, and Greene, Tom

Abstract

Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)—ie, the eGFR slope.

Published
2021
Full Text
View/download PDF

249. Frequency of Intradialytic Hypotension Events Do Not Increase with Oral Nutritional Supplementation during Hemodialysis Treatment: A Randomized Controlled Trial

Author

Ramos-Acevedo, Samuel, González-Ortiz, Ailema, Serralde-Zúñiga, Aurora E., Colín-Ramírez, Eloisa, Miranda-Alatriste, Paola, López-Cisneros, Sonia, Rodríguez-González, Norberto, Correa-Rotter, Ricardo, Atilano-Carsi, Ximena, and Espinosa-Cuevas, Ángeles

Abstract

This study aimed to compare the effect of the use of a renal-specific oral nutritional supplement (RS-ONS) during hemodialysis sessions and the use of RS-ONS at home on the incidence of intradialytic hypotension.

Published
2021
Full Text
View/download PDF

250. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

Author

Saag, Kenneth G., Emkey, Ronald, Schnitzer, Thomas J., Brown, Jacques P., Hawkins, Federico, Goemaere, Stefan, Thamsborg, Gorm, Liberman, Uri A., Delmas, Pierre D., Malice, Marie-Pierre, Czachur, Michelle, Lane, Nancy, Correa-Rotter, Ricardo, Yanover, Melissa, Westhoven, Rene, Epstein, Sol, Adachi, Johnathan A., Poubelle, Patrice, Melo-Gomes, Jose, and Rodriguez-Portales, Jose A.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results